IP Library › Granted Patent US 12,435,112
Granted Patent B2
US 12,435,112 · App. 17/769,689 · Granted Oct 7, 2025

Adenovirus comprising a modified adenovirus hexon protein

Inventors: Stefan Kochanek (Blaubeuren, DE); Lea Krutzke (Sachsenheim, DE); Robin Nilson (Ulm, DE); Olivia Lübbers (Neu-Ulm, DE)
Assignee: UNIVERSITÄT ULM
C07K14/005A61K35/28C12N15/86C12N2710/10322C12N2710/10332C12N2710/10343C12N2810/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,112
App. No.
17/769,689
Granted
Oct 7, 2025
Kind
B2
Abstract

The invention discloses a human adenovirus species C having a capsid which comprises a modified adenovirus hexon protein, wherein the modified adenovirus hexon protein has a modified HVR1 region, wherein the modified HVR1 region has the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1). The invention further discloses the adenovirus of the disclosure for use in treating or preventing a human disease. The invention further discloses a nucleic acid encoding the modified adenovirus hexon protein. The invention further discloses the use of an adenovirus according to the disclosure for transducing mesenchymal stromal cells (MSCs) or tumor cells. The invention further discloses an in vitro method for transducing MSCs and a transduced MSC obtainable by the method. The invention further discloses the transduced MSC of the disclosure for use in treating a disease.

Claims (22)

1. A human adenovirus species C comprising a capsid which comprises a modified adenovirus hexon protein, wherein the modified adenovirus hexon protein has a modified HVR1 region, wherein the modified HVR1 region comprises the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1).

2. The adenovirus of claim 1 , wherein the adenovirus is adenovirus type 5.

3. The adenovirus of claim 1 , wherein the adenovirus is an adenovirus vector or an oncolytic adenovirus.

4. The adenovirus of claim 1 , wherein the adenovirus comprises a transgene.

5. The adenovirus of claim 1 , wherein the capsid comprises at least one additional capsid modification.

6. A method of treating a human disease in a patient in need thereof, comprising administering the adenovirus of claim 1 to the patient.

7. A nucleic acid encoding a modified adenovirus hexon protein of a human adenovirus species C, wherein the modified adenovirus hexon protein comprises a modified HVR1 region, wherein the modified HVR1 region comprises the sequence of SEQ ID NO.: 1.

8. The nucleic acid of claim 7 , wherein the nucleic acid comprises the sequence of SEQ ID NO.: 2.

9. A method of transducing mesenchymal stromal cells (MSCs) or tumor cells comprising contacting the cells with the adenovirus of claim 1 .

10. The method of claim 9 , further comprising contacting the cells with a transduction enhancer for transducing MSCs.

11. The method of claim 10 , wherein the transduction enhancer is selected from the group consisting of coagulation factor X, spermidine, spermine, hexadimethrine bromide, poly-L-lysine and lactoferrin.

12. An in vitro method for transducing MSCs, the method comprising the step of:

contacting a plurality of MSCs with an adenovirus of claim 1 .

13. The method according to claim 12 , wherein the plurality of MSCs is further contacted with a transduction enhancer.

14. A transduced MSC obtainable by the method of claim 12 .

15. A method of treating a disease in a patient in need thereof, comprising administering the transduced MSC of claim 14 .

16. The adenovirus of claim 5 , wherein the additional capsid modification is a modified adenovirus fiber protein.

17. The method according to claim 13 , wherein the transduction enhancer is selected from the group consisting of coagulation fac-tor X, spermidine, spermine, hexadimethrine bromide, poly-L-lysine and lactoferrin.

18. The adenovirus of claim 1 , wherein the modified HVR1 region consists of the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1).

19. The nucleic acid of claim 7 , wherein the modified HVR1 region consists of the sequence of SEQ ID NO.: 1.

20. The nucleic acid of claim 7 , wherein the nucleic acid consists of the sequence of SEQ ID NO.: 2.

21. The adenovirus of claim 1 , wherein the modified HVR1 region consists of the sequence of SEQ ID NO.: 43.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2022
From: KOCHANEK, STEFAN; KRUTZKE, LEA; NILSON, ROBIN; LÜBBERS, OLIVIA
To: UNIVERSITÄT ULM
Reel/Frame 061667/0423 →
Priority Claims (1)
EP 19204420 · Oct 21, 2019 · regional
Continuity (1)
Related Publication 20220380411A1 · Dec 1, 2022
References Cited (24)
US 11155599B2 · Fueyo-Margareto · 2021 [cited by examiner]
US 20130302313A1 · Yu et al. · 2013 [cited by applicant]
US 20140377294A1 · Fueyo-Margareto · 2014 [cited by examiner]
CA 3090859A1 · 2019 [cited by examiner]
JP 2016521709A · 2016 [cited by applicant]
JP 2017518765A · 2017 [cited by applicant]
WO 2014197638A3 · 2015 [cited by applicant]
WO 2015173578A1 · 2015 [cited by applicant]
WO 2016049201A1 · 2016 [cited by applicant]
WO 2016118433A1 · 2016 [cited by applicant]
Khare R, Reddy VS, Nemerow GR, Barry MA. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol. Feb. 2012;86(4):2293-301. (Year: 2012). [cited by examiner]
Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrin… [cited by examiner]
Lucas T, Benihoud K, Vigant F, Schmidt CQ, Wortmann A, Bachem MG, Simmet T, Kochanek S. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cance… [cited by examiner]
Krutzke, L , et al., “Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity”, Journal of Controlled Release 235, 379-392 (2016). [cited by applicant]
Patent Cooperation Treaty , International Searching Authority, Search Report and Written Opinion for PCT/EP2020/079494, 16 pages, dated Jan. 25, 2021. [cited by applicant]
Jonsson, M , et al., “Coagulation Factors IX and X Enhance Binding and Infection of Adenovirus Types 5 and 31 in Human Epithelial Cells”, Journal of Virology 83 (8), 3816-3825 (2009). [cited by applicant]
Zaiss, A , et al., “Differential Effects of Murine and Human Factor X on Adenovirus Transduction via Cell-surface Heparan Sulfate”, Journal of Biological Chemistry 286 (28) 24535-24543 (2011). [cited by applicant]
Zhao, C , et al., “Adenovirus-Mediated Gene Transfer in Mesenchymal Stem Cells Can Be Significantly Enhanced by the Cationic Polymer Polybrene”, PLOS One 9 (3), e92908, 1-8 (2014). [cited by applicant]
Alba, R , et al., “Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer”, Blood 114, 965-971 (2009). [cited by applicant]
Alemany, R. , et al., “Blood clearance rates of adenovirus type 5 in mice”, J Gen Virol 81, 2605-2609 (2000). [cited by applicant]
Fekete, N. , et al., “GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC”, PLOS One 7, e43255 (2012). [cited by applicant]
Fekete, N. , et al., “Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: pro… [cited by applicant]
Khare, R. , et al., “Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors”, J Virol 86, 2293-2301 (2012). [cited by applicant]
Kirby, I , et al., “Identification of Contact Residues and Definition of the CAR-Binding Site of Adenovirus Type 5 Fiber Protein”, J Virol 74, 2804-2813 (2000). [cited by applicant]